Our mission

The research activities of the IPPON consortium are at the forefront of integrated personalized cancer medicine. For different cancers in urgent need for improved therapeutic outcomes, our joint mission is:

1. To develop novel and more effective therapeutic strategies;
2. To improve the detection and understanding of mechanisms driving therapeutic resistance;
3. To identify and validate biomarkers for early detection and personalized therapy.

The strong interdisciplinary partnership between basic, translational and clinical researchers within the IPPON consortium enables us to tackle burning research questions and clinical unmet needs, and leads us to meaningful advances in the highly innovative and rapidly changing field of personalized cancer medicine and to improved patient outcomes both in terms of survival and quality of life.

Collaborations

IPPON is always open to collaborations with public and non-public research institutes and companies in order to create more opportunities leading to improved cancer therapy. For more information you can always contact us.​

​Radionuclide Imaging of Cytotoxic Immune Cell Responses to Anti-Cancer Immunotherapy​

​Pathophysiology and Treatment of Pancreatic Neuroendocrine Neoplasms (PNENS): New Developments​

​Molecular Imaging of Apoptosis: The Case of Caspase-3 Radiotracers

​Modulating the Antioxidant Response for Better Oxidative Stress-Inducing Therapies: How to Take Advantage of Two Sides of the Same Medal?

​Recent Advances of Immune Checkpoint Inhibition and Potential for (Combined) TIGIT Blockade as a New Strategy for Malignant Pleural Mesothelioma

​Targeting hedgehog signaling in pancreatic ductal adenocarcinoma

​The CD70-CD27 axis in oncology: the new kids on the block

​Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib

​Evaluation of a new online cognitive assessment tool in breast cancer survivors with cognitive impairment: a prospective cohort study

​Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR-targeting agents to treat head and neck squamous cell carcinoma​

Promotor

Prof. dr. Marc Peeters

Co-promotors

Prof. dr. Jeroen Hendriks, Prof. dr. Filip Lardon, Prof. dr. Patrick Pauwels, Prof. dr. Evelien Smits, Prof. dr. Peter van Dam, Prof. dr. Wim Vanden Berghe, Prof. dr. Tim Van Den Wyngaert

Research manager

​Delphine Quatannens​

Associated members

​Prof. dr. Filipe Elvas, Prof. dr. Hans Prenen, Prof. dr. Steven Van Laere, ​Prof. dr. Christophe Vulsteke, ​​Prof. dr. An Wouters